GSK is hosting the third annual RespiVerse Meeting in Bangkok, Thailand. The event brings together renowned international ...

GSK hosted the third annual RespiVerse Meeting on December 13 and 14 in Bangkok, Thailand. The event brought together renowned international speakers and healthcare professionals from 17 countries to ...

The $14.75-per-share deal will add P2X3 antagonist camlipixant to GSK’s respiratory pipeline, a drug which the UK-headquartered big pharma reckons could be ready for launch in 2026, although it ...

GlaxoSmithKline (GSK)’s B7-H3-targeted antibody-drug conjugate (ADC), GSK’227 has gained priority medicines (PRIME) ...

Bank of America Securities analyst Graham Parry has maintained their bearish stance on GSK stock, giving a Sell rating on December 11.Pick the ...

A new antibody from Merck would join a market teeming with new entries, but plenty of regulatory and financial uncertainty.

"We research and develop a portfolio of vaccines, targeted biological products, and inhaled medicines at the forefront of the respiratory sector, aiming to improve outcomes and enhance the lives of ...

GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of phase 3 trials presented at the European Respiratory Society (ERS ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a ...